论文部分内容阅读
The various phase 2/3 clinical trials with CCR5 antagonists encompass both treatment-experienced as well as naive HIV-infected individuals.Thus,future data will indicate whether chemokine receptor antagonists are best used as components of initial treatment regimen or reserved for use in later regimens.Unexpectedly,GSK announced it halted the studies with aplaviroc after a naive patient,was found with elevated liver enzymes and bilirubin.